APO-TRYPTOPHAN 250 MG
TRYPTOPHAN : 250 MG · DIN 02248537 · APOTEX INC
Health Canada status: APPROVED
What is APO-TRYPTOPHAN?
APO-TRYPTOPHAN 250 MG contains TRYPTOPHAN : 250 MG. It is listed in the Health Canada Drug Product Database under DIN 02248537, held by APOTEX INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as approved, status dated 09-Dec-2003. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 02248537 |
|---|---|
| Brand name | APO-TRYPTOPHAN |
| Generic / active ingredient | TRYPTOPHAN : 250 MG |
| Manufacturer | APOTEX INC |
| Strength | 250 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | N06AX02 TRYPTOPHAN |
| AHFS class | 28:16.04 |
| Biosimilar | No |
| Health Canada status | APPROVED |
| Status date | 09-Dec-2003 |
What can be used instead?
Other Canadian products sharing ATC code N06AX02 TRYPTOPHAN. 11 of 20 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-TRYPTOPHAN | 1 G | TABLET | APOTEX INC | MARKETED | DIN 02248539 |
| APO-TRYPTOPHAN | 500 MG | TABLET | APOTEX INC | MARKETED | DIN 02248538 |
| APO-TRYPTOPHAN | 500 MG | CAPSULE | APOTEX INC | MARKETED | DIN 02248540 |
| APO-TRYPTOPHAN | 750 MG | TABLET | APOTEX INC | MARKETED | DIN 02458721 |
| TEVA-TRYPTOPHAN | 500 MG | TABLET | TEVA CANADA LIMITED | MARKETED | DIN 02240333 |
| TEVA-TRYPTOPHAN | 500 MG | CAPSULE | TEVA CANADA LIMITED | MARKETED | DIN 02240334 |
| TRYPTAN | 1 G | TABLET | BAUSCH HEALTH, CANADA INC. | MARKETED | DIN 00654531 |
| TRYPTAN | 250 MG | TABLET | BAUSCH HEALTH, CANADA INC. | MARKETED | DIN 02239326 |
| TRYPTAN | 500 MG | TABLET | BAUSCH HEALTH, CANADA INC. | MARKETED | DIN 02029456 |
| TRYPTAN | 500 MG | CAPSULE | BAUSCH HEALTH, CANADA INC. | MARKETED | DIN 00718149 |
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.